Article
Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases.
Applied immunohistochemistry & molecular morphology : AIMM - 1 Mar 2009
Liu Ting, Willmore-Payne Carlynn, Layfield Lester J, Holden Joseph A
Abstract excerpt
Oncogenic activating mutations in the cytosolic serine/threonine kinase, BRAF, have been reported in a variety of neoplasms. BRAF relays signals from membrane-bound RAS downstream through the MAP/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) signaling pathway. The presence of BRAF activating mutations suggests the importance of the MAP/ERK kinase pathway for tumor growth and points...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.